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Abstract
Introduction: Burning mouth syndrome (BMS) is characterized by an oral burning sensation in the absence of any 
organic disorders of the oral cavity. Although the cause of BMS is not known, a complex association of biological 
and psychological factors has been identified, suggesting the existence of a multifactorial etiology. 
Material and Method: A PubMed/Medline search was used to identify articles describing the different hypotheses 
regarding the etiology of BMS, as well as the psychological and anatomical data upon which such hypotheses are 
fundamented. 
Results: A review and update was made of the different hypotheses relating to the etiology of BMS (psychogenic 
factors, hormone disorders, neuropathic alterations, oral phantom pain, neuroplasticity and neuroinflammation), 
with a view to globally establishing possible relationships among them. 
Conclusions: In-depth investigation is needed to clarify the etiopathogenic mechanisms of BMS and its triggering 
factors, in order to develop effective and individualized management strategies that can be extended to patients in 
each different BMS subgroup.
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Introduction
Burning mouth syndrome (BMS) is characterized by 
an oral burning sensation in the absence of any organic 
disorders of the oral cavity. Scala et al. (1) proposed a 
series of differential diagnostic criteria for identifying 
BMS. In this context they established a distinction 
between fundamental and additional criteria for 
diagnosing the disease (Table 1). 
Although different etiological classifications of BMS 
have been developed, the true cause underlying the 
syndrome and which may fully explain the disease 
process has not been clearly established. As a result, it 
is difficult to find a classification capable of including 
all possible presentations of BMS. 
A number of hypotheses have been proposed to 
explain the etiopathogenic mechanism of BMS. The 
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first studies attributed great importance to endocrine 
alterations and tissue degenerative phenomena inherent 
to aging. Posteriorly, research into the etiology of 
BMS has explored neuropathic disorders as well as 
psychopathological factors, due to the high incidence 
of the latter in patients with BMS. In this context, a 
complex association of biological and psychological 
factors has been identified, suggesting the existence 
of a multifactorial etiology (2). Debate on the role of 
these factors in the etiology of BMS has led to many 
hypotheses, though no single theory has received 
unanimous acceptance to date.
The present study offers a review and update of 
the different hypotheses relating to the etiology of 
BMS, with a view to globally establishing possible 
relationships among them.
Search Method
A PubMed/Medline search was used to identify 
articles describing the different hypotheses regarding 
the etiology of BMS, as well as the psychological 
and anatomical data upon which such hypotheses are 
fundamented.
Results
The present review has been made considering the three 
basic references in the etiology of BMS identified to 
date: psychological disorders, hormone alterations and 
disorders of the nervous system.
1.- Psychological disorders such as depression and 
anxiety play an important role in the modulation of pain 
perception, being able to increase or decrease nerve 
transmission from the peripheral pain receptors, and 
modifying individual pain perception - reducing the 
pain threshold and thus causing normal stimuli to be 
perceived as painful (3).
It is reasonable to relate BMS to such psychological 
disorders, since they all share common features. 
In effect, these disorders are all characterized by 
unpleasant sensations, chronic pain, and the absence of 
any clear organic disorder capable of accounting for the 
patient symptoms (3). 
The classical description of depression and anxiety 
concomitant to BMS suggested an association between 
the latter and psychological problems. In addition, 
improvements in BMS have been observed as a result of 
cognitive-behavioral therapy and the use of anxiolytic 
drugs. This indicates that psychological disorders may 
predispose to the development of BMS, though the way in 
which they might influence its etiology remains unclear. 
However, some authors suggest that these psychological 
disorders are more a consequence of BMS than a cause 
of the syndrome (1).
In any case, different studies have confirmed that 
BMS patients have a high prevalence of psychological 
problems such as anxiety, depression, irritability, and 
an increased desire to isolate themselves, compared 
with the control subjects (4,5). 
On the other hand, although psychological factors 
are present in a large proportion of all cases of BMS, 
a substantial percentage on individuals develop the 
syndrome without any psychological disorders (6). This 
indicates that psychological disorders are not the only or 
exclusive cause underlying BMS.
2.- The prevalence of BMS is greater among females, 
and particularly in middle-aged and elderly women. 
The age-related reduction in estrogen and progesterone 
levels favors dryness of the mucosal membranes, 
and psychological disturbances are more frequent in 
middle-aged and elderly women. Based on the existing 
evidence, menopause can be associated to an increased 
risk of developing BMS (7). This hypothesis in turn 
is supported by the good results obtained with oral 
hormone (estrogen) replacement therapy in application 
to the symptoms of xerostomia (8).
3.- Lastly, the presence of sensory alterations such as 
changes in heat tolerance, reduced and altered taste 
sensation, and increased excitability of the blink reflex 
in patients with BMS points to the existence of a 
biological basis related to alterations of both the central 
and peripheral nervous system (9,10). At present, BMS 
is regarded as a painful condition involving neuropathic 
mechanisms, as evidenced by the burning nature of the 
pain. Patients diagnosed with BMS present symptoms 
that are characteristic of trigeminal nerve disorders 
(alterations in pain perception and neuron transmission, 
and increased excitability of the trigeminal vascular 
system), suggesting the possibility that while BMS 
presents a multifactorial etiology, the underlying basis 
of the syndrome is neuropathic.
Immunohistochemical studies have shown the presence 
Table 1. Criteria developed by Scala for the diagnosis of burning 
mouth syndrome.
FUNDAMENTAL INCLUSION CRITERIA:
1. Daily and deep burning sensation of the oral mucosa (bilateral) 
2. Burning sensation for at least 4-6 months 
3. Constant intensity, or increasing intensity during the day 
4. No worsening on eating or drinking. The symptoms may improve 
5. No interference with sleep 
ADDITIONAL INCLUSION CRITERIA:
6. Dysgeusia and/or xerostomia 
7. Sensory or chemosensory alterations 
8. Mood changes or psychopathological alterations 
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of alterations in the small-diameter nerve fibers (C 
fibers) in patients with BMS. However, other studies 
have evidenced other anatomical alterations. In effect, 
some patients show neuropathic signs affecting both 
larger- and smaller-diameter nerve fibers. It therefore 
may be postulated that BMS is a consequence of both 
generalized alterations and disorders at different levels 
of the trigeminal system (11). 
The existence of an enhanced blink reflex in some patients 
with BMS points to a central nervous system alteration 
correlated to dopaminergic system dysfunction (9). 
Diminished presynaptic dopaminergic inhibition would 
increase dopamine release into the interneuronal space, 
with enhanced neuron excitability manifesting as an 
increased blink reflex (9,12). Posteriorly, dopaminergic 
system dysfunction was confirmed in patients with 
BMS on evaluating dopaminergic function in the 
brainstem of such patients (13), and on observing a 
decrease in endogenous dopamine levels in the putamen 
of individuals with BMS (14).
Thus, BMS shares a range of characteristics with other 
forms of chronic pain (5). The alterations underlying 
chronic pain symptoms may result from changes in 
central nervous system function. Hyperstimulation of 
the N-methyl-D-aspartic acid (NMDA) receptors of 
the dorsal trunk neurons may lead to neuroplasticity 
phenomena secondary to hyper-excitation of these 
neurons (15). Neuroplasticity occurs when a neuron 
continuously receives nociceptive signals that produce 
NMDA receptor activation of the contiguous neurons 
– giving rise to enhanced cell sensitivity phenomena 
(15,16). As a result of such neuron sensitization, common 
stimuli usually interpreted as being harmless (such 
as irritation produced by dentures) are reinterpreted 
by the central nervous system as being located above 
the pain threshold and therefore of a harmful nature 
(16). Likewise, sustained stress in denture wearers can 
induce continuous involuntary tongue movements-this 
in turn generating constant sensory stimulation capable 
of triggering pain sensations as a consequence of 
hyperstimulation, as in certain cases of BMS (10).
It has also been suggested that BMS may originate 
form neurological alterations located at peripheral 
level. Such peripheral alterations could be related to the 
density and/or functionality of the membrane receptors 
present in the oral mucosa. This hypothesis is supported 
by the observed local oral mucosal receptor effects of 
clonazepam, which to date has been found to be the most 
effective treatment for the symptoms of BMS (17). 
Other authors have suggested that BMS behaves as a 
form of oral phantom pain. Some alteration in taste 
function would allow stimulation of the taste nerve 
endings to generate both excitatory and inhibitory 
signals (13). In healthy subjects, the chorda tympani 
nerve receives taste sensation from the anterior part 
of the tongue, with inhibition of the taste response 
in the posterior region of the tongue, while the 
glossopharyngeal nerve receives taste sensation from 
the posterior zone of the tongue (14). It is also known that 
taste sensation conveyed by the chorda tympani nerve 
inhibits the area of the brain that receives the afferent 
impulses from the glossopharyngeal and trigeminal 
nerves. It has been suggested that damage to the chorda 
tympani nerve would block its inhibitory action upon 
the glossopharyngeal and trigeminal nerves – thus 
allowing intensification of the trigeminal sensations, 
which include oral pain, touch sensation, dry mouth and 
phantom sensations (18). Different findings support this 
theory and explain the increased prevalence of BMS in 
postmenopausal women (18-20) (Table 2).
In recent years, different studies have pointed to 
neuronal inflammation as a key element in the 
physiopathology of different disorders characterized by 
chronic pain (11). The clinical features of BMS suggest 
a possible participation of neuronal inflammation in the 
etiopathogenesis of the syndrome, along with some of 
the other previously considered pathogenic mechanisms. 
Three hypotheses have been proposed in this sense: 
• A first hypothesis suggests that neuronal inflammation 
may be mediated by a classical axonal reflex that would 
activate a group of nociceptors, causing them to release 
neuropeptides at trigeminal terminal branch level. 
• A second hypothesis points suggests the existence 
of an indirect reflex that would develop in the afferent 
nerves of the oral cavity, followed by processing at 
central level in the trigeminal nerve, and the induction 
of a response at autonomic nervous system level. 
In these two models the appearance of characteristic 
BMS symptoms could be explained by the neurogenic 
   x Bitter taste sensory capacity decreases with menopause (19).  
x Individuals with burning mouth syndrome suffer altered or abolished 
bitter taste sensory capacity (18). The chorda   tympani nerve conducts 
information from the anterior lingual zone, where the bitter taste papillae are 
located. Altered bitter taste sensation in patients with burning mouth 
syndrome could reflect damage to the chorda tympani nerve. 
x In patients with burning mouth syndrome, topical anesthesia increases 
oral burning (19,20), in the same way as topical anesthesia intensifies 
phantom pain sensation in some patients. The increased phantom pain 
sensations following anesthesia are explained by blockade of the inhibitory 
activity that controls them (18,20). 
x The maximum pain intensity experienced by patients with burning mouth 
syndrome is correlated to tongue papilla density; it therefore may be assumed 
that patients with burning mouth syndrome who are sensitive to bitter taste 
are super-sensitive to taste (18). 
Table 2. Evidence supporting burning mouth syndrome as a 
form of oral phantom pain.
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change theory. Such change occurs when an efferent 
central nervous system signal produces neuropeptide 
release and inflammation in a zone without direct local 
stimulation. 
• A third hypothesis is related to the capsaicin receptors, 
which have dual efferent and sensory activities. 
These receptors, which are found in the C-polymodal 
nociceptors, would be implicated in the regulation of 
the events associated to neurogenic inflammation, and 
would be activated upon receiving afferent signals and 
the simultaneous release of neuropeptides from the 
same nerve endings. 
The neuroinflammatory model could account for the 
efficacy of gabaergic drugs in controlling the symptoms 
of BMS. These drugs would not only act at central 
level, since gabaergic receptor presence has also been 
described in peripheral tissues, and they possibly may 
also be present in peripheral nerve endings; as a result, 
the stimulation of such receptors mediated by these 
drugs could modulate the release of inflammatory 
neuropeptides. Neuroinflammation may occur in 
patients with normal or damaged nerve fibers, and is 
compatible with the histological findings reported by 
different authors in BMS. This hypothesis is supported 
by the efficacy of low-dose prazepam in controlling the 
symptoms of BMS in patients participating in a pilot 
study (11). Prazepam elicits a minimal effect at central 
nervous system level that is insufficient to explain 
resolution of the disease, and the results of the study 
could be interpreted in terms of the gabaergic action of 
the drug upon the peripheral nerve fibers (11).
Discussion
The present study has reviewed the different theories 
proposed to explain the etiology of primary or idiopathic 
burning mouth syndrome (BMS). In this context, 
secondary BMS should be regarded as a different 
process in which oral burning sensation is simply 
produced by some objective and tractable local or 
systemic condition such as hyposialia, oral infections, 
autoimmune disorders of the oral mucosa such as lichen 
planus, nutritional deficiencies, allergies, irritation 
attributable to esophageal reflux, the administration of 
certain drugs, and some endocrine disorders (21).
Precise knowledge of the etiology of BMS would allow 
us to define patient subpopulations with differential 
features, and which presently are all grouped under the 
term of primary BMS. A distinction has already been 
made among three different clinical forms of BMS 
which have been associated to different causes (1). 
The existence of non-identified subpopulations with 
etiologically distinct forms of BMS is fundamented upon 
the different therapeutic responses shown by the patients 
included in the different studies carried out to evaluate 
drug substances for the treatment of BMS. If all cases of 
BMS were of one same origin, then the drugs evaluated 
would be expected to exhibit similar efficacy rates in 
all the treated patients. Another possible explanation 
for the differences in drug treatment response could be 
that the efficacy of a given agent might differ according 
to the stage of the disease. This would suggest the 
possibility of classifying BMS according to the stage of 
the syndrome – though no such classification has been 
developed to date. Each patient subpopulation would 
require a different management approach in order to 
control the symptoms and resolve the disease process. 
Further in-depth investigation is needed to clarify the 
etiopathogenic mechanisms of BMS and its triggering 
factors, in order to develop effective and individualized 
management strategies that can be extended to patients 
in each different primary BMS subgroup (17).
Conclusion
Although different etiological theories have been 
proposed to explain primary burning mouth syndrome, 
none have received universal acceptance to date. 
While the origin of BMS remains unclear, a range of 
factors are believed to be implicated. It seems clear 
that psychological factors and alterations of the central 
nervous system are involved, though we do not know 
whether they are a cause or a consequence of BMS. In 
addition, the influence and connections of such factors 
in relation to alterations at peripheral nervous system 
level have not been established. 
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